Researchers in the University at Buffalo’s Department of Neurology shared their findings through more than 30 presentations at the American Academy of Neurology’s 67th Annual Meeting.

The Howard Hughes Medical Institute has selected second-year University at Buffalo medical student Niema Razavian for its Medical Research Fellows Program.


Students in biomedical engineering and medicine are principals in the biotechnology venture that won a University at Buffalo entrepreneurship competition.

At the 2015 Medical Student Research Forum, aspiring physician-scientists showcased 45 original research projects they conducted at the University at Buffalo, its partner health care agencies and institutions nationwide.

An international team led by Jonathan F. Lovell, PhD, assistant professor of biomedical engineering, has created a nanoparticle that may pave the way for “hypermodal” imaging — the ability to merge results from six different imaging modes using one contrast agent.

University at Buffalo researchers have designed a biomedical device that could make chemotherapy more efficient, reduce its side effects and improve how doctors treat some of the most deadly forms of cancer.

With the goal of improving chemotherapy, Jennifer A. Surtees, PhD, associate professor of biochemistry, will study what makes cancer cells sensitive or resistant to different DNA-damaging drugs.

Research led by a student in UB’s Medical Scientist Training Program is featured on the cover of the world’s most frequently cited cancer journal.

Wilma A. Hofmann, PhD, assistant professor of physiology and biophysics, will study cellular processes that cause high levels of unsaturated fats to increase the metastatic potential of prostate cancer cells.


Nearly 100 student-scientists from across the country showcased their original biomedical research during the 2014 Buffalo Summer Research Day.


Using tiny modified liposomes, University at Buffalo researchers are developing a chemotherapy delivery method that could improve cancer treatment, reduce its side effects and boost knowledge about the disease.


Actively seeking and successfully obtaining a creative mix of funding, Matthew J. Barth, MD, research assistant professor of pediatrics, is pursuing promising research aimed at helping children with B-cell non-Hodgkin lymphoma overcome resistance to treatment.


With the ultimate goal of designing new immunotherapeutic strategies, Richard B. Bankert, VMD, PhD, professor of microbiology and immunology, and his team are working to re-activate cancer-killing T cells in a tumor’s microenvironment.


Through her fledgling start-up firm, University at Buffalo researcher Kate Rittenhouse-Olson, PhD ’84, is turning a mouse antibody she created into a promising cancer-fighting therapy for humans.


More than 100 student scientists from across the country showcased their original research during this summer’s University at Buffalo Biomedical Research Day.

Piero R. Bianco, PhD, associate professor of microbiology and immunology, will use a $1.8 million grant to develop the first clear model of a biochemical DNA repair mechanism needed to stave off cancer.

The UB Clinical and Translational Science Institute showcased award-winning studies and novel technologies developed jointly by UB researchers and collaborators.


Kunle Odunsi, director of RPCI’s Center for Immunotherapy and UB professor of gynecology and obstetrics, is leading a phase 1 clinical trial of the dendritic cell vaccine.